Why NexCAR19, India's own CAR-T cell therapy, is a boon for blood cancer patients

In a promising development in the area of cancer treatment, NexCAR19, India's first indigenously developed CAR-T cell therapy is now available for commercial use. It can be given to cancer patients, especially those who are suffering from blood cancer, including leukaemia and lymphomas

Related Keywords

India ,Bombay ,Maharashtra ,Mumbai ,Kokilaben Dhirubhai Ambani ,Subhasis Chaudhuri ,Preetam Jain ,Tata Memorial Center ,Indian Institute Of Technology Bombay ,Central Drugs Standard Control Organisation ,Indian Institute ,Technology Bombay ,Tata Memorial Hospital ,Kokilaben Dhirubhai Ambani Hospital ,Chimeric Antigen Receptort Cell ,Acute Lymphocytic ,Cart Cell Therapy ,Nexcar19 Cart Cell Therapy ,Kokilaben Dhirubhai Ambani Hospital Nexcar19 ,Nexcar19 Blood Cancer ,